Abstract
The recent coronavirus disease 2019 (COVID-19) outbreak has highlighted the inadequacy of our ability to respond to newly emerging viruses. Antiviral medications are the most effective means of combating the pandemic, yet their diminishing efficacy and a large population of unvaccinated individuals will create a fertile environment for the virus’s propagation and the emergence of novel variants, posing an ongoing risk of infection for vulnerable populations with compromised immune systems. To treat those infected, effective treatments must be developed. In this review, we discuss a breakthrough in engineered antibody fragments that could provide a protective barrier against the onslaught of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants as well as future other viral infections.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
